▼ 0.98%
prev close
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Congressional Trades
2
All tracked trades
Members Trading
1
Unique members
Net Activity
+2
2 buys · 0 sells
Members Who Traded This Stock
2 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-09-22 | BBIOBridgeBio Pharma, Inc. - Common Stock | Buy | $1,001 - $15,000 | 190d ago | — | |
| 2025-08-08 | BBIOBridgeBio Pharma, Inc. - Common Stock | Buy | $1,001 - $15,000 | 218d ago | — |
2025-09-22
Gilbert Cisneros
BBIO
Amount
$1,001 - $15,000
Filed
190d ago
2025-08-08
Gilbert Cisneros
BBIO
Amount
$1,001 - $15,000
Filed
218d ago
Recent News
Powered by Polygon.io
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
Blue Owl, Genuine Parts, And Okta Are Among Top 10 Large Cap Losers Last Week (Feb. 16-Feb. 20): Are the Others in Your Portfolio?
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Trade Timeline
Congressional activity, newest first
Gilbert Cisneros
2025-09-22 · Purchase
$1,001 - $15,000
Gilbert Cisneros
2025-08-08 · Purchase
$1,001 - $15,000